BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11834427)

  • 1. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
    Sneppen SB; Hoeck HC; Kollerup G; Sørensen OH; Laurberg P; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
    Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E
    Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
    Finkenstedt G; Gasser RW; Höfle G; Watfah C; Fridrich L
    Eur J Endocrinol; 1997 Mar; 136(3):282-9. PubMed ID: 9100553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
    Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
    Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults.
    Kann P; Piepkorn B; Schehler B; Andreas J; Lotz J; Prellwitz W; Beyer J
    Clin Endocrinol (Oxf); 1998 May; 48(5):561-8. PubMed ID: 9666867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B; Kann PH
    Med Klin (Munich); 2004 Oct; 99(10):569-77. PubMed ID: 15490072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
    Longobardi S; Keay N; Ehrnborg C; Cittadini A; Rosén T; Dall R; Boroujerdi MA; Bassett EE; Healy ML; Pentecost C; Wallace JD; Powrie J; Jørgensen JO; Saccà L
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
    Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density in patients with growth hormone deficiency: does a gender difference exist?
    Hitz MF; Jensen JE; Eskildsen PC
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):783-91. PubMed ID: 17121531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study.
    Sääf M; Hilding A; Thorën M; Troell S; Hall K
    Eur J Endocrinol; 1999 May; 140(5):390-9. PubMed ID: 10229902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.
    Beshyah SA; Kyd P; Thomas E; Fairney A; Johnston DG
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):249-54. PubMed ID: 7758229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
    Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
    J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency.
    Kotzmann H; Riedl M; Bernecker P; Clodi M; Kainberger F; Kaider A; Woloszczuk W; Luger A
    Calcif Tissue Int; 1998 Jan; 62(1):40-6. PubMed ID: 9405732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.